Page 139 - 2019_03-Haematologica-web

ActivinA enhances BCP-ALL cell migration
induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010;107(11):5124-5129.
12. Bashir M, Damineni S, Mukherjee G, Kondaiah P. Activin-A signaling promotes epithelial–mesenchymal transition, inva- sion, and metastatic growth of breast can- cer. NPJ Breast Cancer. 2015;1:15007.
13. Taylor C, Loomans HA, Le Bras GF, et al. ActivinA signaling regulates cell invasion and proliferation in esophageal adenocarci- noma. Oncotarget. 2015;6(33):34228- 34244.
14. Bufalino A, Cervigne NK, de Oliveira CE, et al. Low miR-143/miR-145 cluster levels induce ActivinA overexpression in oral squamous cell carcinomas, Which con- tributes to poor prognosis. PLoS One. 2015;10(8):e0136599.
15. Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res. 2005;3(1):50- 61.
16. Salogni L, Musso T, Bosisio D, et al. ActivinA induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood. 2009; 113(23):5848-5856.
17. Watabe T, Nishihara A, Mishima K, et al. TGF-beta receptor kinase inhibitor enhances growth and integrity of embry- onic stem cell-derived endothelial cells. J Cell Biol. 2003;163(6):1303-1311.
18. Balandrán JC, Purizaca J, Enciso J, et al. Pro- inflammatory-related loss of CXCL12 niche promotes acute lymphoblastic leukemic progression at the expense of nor- mal lymphopoiesis. Front Immunol. 2017; 7:666.
19. van den Berk LC, van der Veer A, Willemse ME, et al. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lym- phoblastic leukaemia. Br J Haematol. 2014; 166(2):240-249.
20. Vilchis-Ordoñez A, Contreras-Quiroz A, Vadillo E, et al. Bone marrow cells in acute lymphoblastic leukemia create a proinflam- matory microenvironment influencing nor- mal hematopoietic differentiation fates. Biomed Res Int. 2015; 2015:386165.
21. Roell KR, Reif DM, Motsinger-Reif AA. An introduction to terminology and methodol- ogy of chemical synergy-perspectives from across disciplines. Front Pharmacol. 2017; 8:158.
22. Yuan N, Song L, Zhang S, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lym- phoblastic leukemia. Haematologica. 2015;100 (3):345-356.
23. Pillozzi S, Masselli M, De Lorenzo E, et al. Chemotherapy resistance in acute lym- phoblastic leukemia requires hERG1 chan-
nels and is overcome by hERG1 blockers.
Blood. 2011;117(3):902-914.
24. Barrett DM, Seif AE, Carpenito C, et al.
Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical model- ing. Blood. 2011;118(15):e112-117.
25. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464(7290):852-857.
26. Sison EAR, Brown P. The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Rev Hematol. 2011;4(3):271-283.
27. Sozzani S, Musso T. The yin and yang of ActivinA. Blood. 2011;117(19):5013-5015.
28. Dean M, Davis DA, Burdette JE. ActivinA stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical sig- naling. Cancer Lett. 2017;391:114-124.
29. Zhu J, Liu F, Wu Q, Liu X. ActivinA regu- lates proliferation, invasion and migration in osteosarcoma cells. Mol Med Rep. 2015;11(6):4501-4507.
30. Kang HY, Huang HY, Hsieh CY, et al. ActivinA enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer. J Bone Miner Res. 2009;24(7):1180-1193.
31. Yoshinaga K, Yamashita K, Mimori K, Tanaka F, Inoue H, Mori M. ActivinA caus- es cancer cell aggressiveness in esophageal squamous cell carcinoma cells. Ann Surg Oncol. 2008;15(1):96-103.
32. Chang WM, Lin YF, Su CY, et al. Dysregulation of RUNX2/Activin-A axis upon miR-376c downregulation promotes lymph node metastasis in head and neck squamous cell carcinoma. Cancer Res. 2016;76(24):7140-7150.
33. Tamminen JA, Yin M, Ronty M, et al. Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activa- tion promote cell migration and invasive growth. Exp Cell Res. 2015;332(1):102-115.
34. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell nich- es. Immunity. 2006;25(6):977-988.
35. Lipp P, Reither G. Protein Kinase C: The “Masters” of Calcium and Lipid. Cold Spring Harb Perspect Biol. 2011; 3(7):a004556-a004556.
36. Swulius MT, Waxham MN. Ca(2+)/Calmodulin-dependent Protein Kinases. Cell Mol Life Sci. 2008; 65(17): 2637-2657.
37. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal
dynamics and cellular tension. Nat Rev Mol
Cell Biol. 2010;11(9):633-643.
38. Kobayashi M, Harada K, Negishi M, Katoh
H. Dock4 forms a complex with SH3YL1 and regulates cancer cell migration. Cell Signal. 2014;26(5):1082-1088.
39. Pick R, Begandt D, Stocker TJ, et al. Coronin 1A, a novel player in integrin biol- ogy, controls neutrophil trafficking in innate immunity. Blood. 2017;130(7):847- 858.
40. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22.
41. Csepanyi-Komi R, Wisniewski E. Rac GTPase Activating Protein ARHGAP25 Regulates Leukocyte Transendothelial Migration in Mice. J Immunol. 2016;197 (7):2807-2815.
42. Csepanyi-Komi R, Sirokmany G, Geiszt M, Ligeti E. ARHGAP25, a novel Rac GTPase- activating protein, regulates phagocytosis in human neutrophilic granulocytes. Blood. 2012;119(2):573-582.
43. Ogimoto M, Katagiri T, Mashima K, Hasegawa K, Mizuno K, Yakura H. Negative regulation of apoptotic death in immature B cells by CD45. Int Immunol. 1994;6(4):647-654.
44. LiM,ZhangS,WuN,WuL,WangC,Lin Y. Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3. Sci Rep. 2016;6:23100.
45. Salhia B, Tran NL, Chan A, et al. The gua- nine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am J Pathol. 2008; 173(6):1828-1838.
46. JiangK,LuQ,LiQ,JiY,ChenW,XueX. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immuno- pharmacol. 2017;42:195-202.
47. Lin KT, Gong J, Li CF, et al. Vav3-rac1 sig- naling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and post- treatment recurrence. Cancer Res. 2012; 72(12):3000-3009.
48. Uen YH, Fang CL, Hseu YC, et al. VAV3 oncogene expression in colorectal cancer: clinical aspects and functional characteriza- tion. Sci Rep. 2015;5(1):9360.
49. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120(14):2807-2816.
50. Crazzolara R, Kreczy A, Mann G, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infil- tration in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001;115(3):545- 553.
haematologica | 2019; 104(3)
545